|
Market Closed -
Swiss Exchange
16:30:17 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 112.04 CHF | -0.09% |
|
-13.54% | +2.23% |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease | RE |
| 09-11 | US FDA approves Scholar Rock's muscle weakness drug | RE |
| Market Cap | 261B 225B 213B 193B 362B 24,938B 364B 2,529B 973B 12,687B 980B 959B 40,091B | P/E 2026 * |
19.4x | P/E 2027 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 293B 252B 239B 216B 406B 27,955B 408B 2,835B 1,090B 14,222B 1,099B 1,075B 44,941B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 4.71x |
| Free-Float |
91.66% | Yield 2026 * |
3.21% | Yield 2027 * | 3.35% |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NOVN | Delayed | |
CBOE
| 0QLR | Real-time | |
|
OTC Markets
| NVSEF | Delayed | |
|
London S.E.
| 0QLR | Delayed | |
|
Borsa Italiana
| 1NOVN | End-of-day quote | |
|
Tradegate
| NOT | Real-time | |
|
Xetra
| NOT | Delayed | |
|
Xetra
| NOT | End-of-day quote | |
|
Deutsche Boerse AG
| NOT | End-of-day quote | |
|
Boerse Muenchen
| NOT | Real-time | |
|
Börse Stuttgart
| NOT | Delayed | |
|
Deutsche Boerse AG
| NOT | Delayed | |
|
Mexican S.E.
| NOVN N | End-of-day quote | |
|
CBOE
| 0QLR | Real-time | |
|
Wiener Boerse
| NOVN | End-of-day quote | |
|
CBOE
| Real-time |
Last Transcript : Novartis AG
| 1 day | -0.09% | ||
| 1 week | -13.54% | ||
| Current month | -9.10% | ||
| 1 month | -9.79% | ||
| 3 months | -8.22% | ||
| 6 months | -7.28% | ||
| Current year | +2.23% |
| 1 week | 110.3 |  | 127.22 |
| 1 month | 110.3 | | 132.68 |
| Current year | 107.68 | | 132.68 |
| 1 year | 96.03 | | 132.68 |
| 3 years | 81.1 | | 132.68 |
| 5 years | 72.84 | | 132.68 |
| 10 years | 65.09 | | 132.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/01/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 15/03/2026 |
Karen Hale
CMP | Compliance Officer | 58 | 13/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 31/12/2014 |
| Director/Board Member | 69 | 31/12/2015 | |
Ton Büchner
BRD | Director/Board Member | 61 | 31/12/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/05/26 | Sell | -5,200 | 0.0003% | |||
| 04/05/26 | Sell | 6,800 | 0.0003% | |||
| 17/02/26 | Sell | 30,743 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | -13.54% | +13.34% | +24.95% | 261B | |
| -0.65% | -2.93% | +47.70% | +86.17% | 994B | |
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | |
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | |
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | |
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | |
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | |
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | |
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | |
| +0.25% | -2.57% | +16.13% | -18.83% | 158B | |
| Average | -0.63% | -5.44% | +21.49% | +34.43% | 366.28B | |
| Weighted average by Cap. | -0.47% | -4.34% | +30.32% | +51.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.64B 49.66B 47.02B 42.62B 79.96B 5,507B 80.37B 558B 215B 2,802B 216B 212B 8,853B | 61.32B 52.83B 50.02B 45.34B 85.06B 5,858B 85.49B 594B 228B 2,980B 230B 225B 9,417B |
| Net income | 14.19B 12.23B 11.58B 10.49B 19.69B 1,356B 19.79B 137B 52.87B 690B 53.29B 52.12B 2,179B | 15.75B 13.57B 12.85B 11.64B 21.84B 1,504B 21.95B 153B 58.67B 765B 59.14B 57.84B 2,418B |
| Net Debt | 31.58B 27.21B 25.77B 23.36B 43.82B 3,017B 44.04B 306B 118B 1,535B 119B 116B 4,851B | 27.9B 24.04B 22.76B 20.63B 38.7B 2,665B 38.9B 270B 104B 1,356B 105B 102B 4,284B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | CHF 112.04 | -0.09% | 2,803,406 |
| 10/09/26 | CHF 112.14 | +0.43% | 3,279,444 |
| 09/09/26 | CHF 111.66 | -0.13% | 4,317,913 |
| 08/09/26 | CHF 111.80 | -10.89% | 10,430,648 |
| 07/09/26 | CHF 125.46 | -3.18% | 3,116,102 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
